Skip to content

Study · In vitro (cells) · 2021

10 results

The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells via scavenging mitochondrial ROS and maintaining the stability of mitochondrial dynamics.

Peng X, Wang K, Zhang C, Bao JP, Vlf C, Gao JW, Zhou ZM, Wu XT

Free radical research22 Dec 2021Cited by 36 (Europe PMC)

PMID34903138 (opens in a new tab)DOI10.1080/10715762.2021.2018426 (opens in a new tab)PepBankPUB-34903138
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In nucleus pulposus cells, SS‑31 ameliorated the LPS-induced loss of cell viability.

    In plain wordsIn lab cells, SS‑31 reduced the loss of cell viability caused by LPS.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCell viability
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Cell viability and death · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 ameliorated lipopolysaccharide (LPS)-induced loss of cell viability
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  2. 02LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 ameliorated LPS-induced reactive oxygen species production.

    In plain wordsIn lab cells, SS‑31 lowered the reactive oxygen species caused by LPS.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseROS production
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Oxidative stress · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 ameliorated lipopolysaccharide (LPS)-induced loss of cell viability, ROS production, and apoptosis in NP cells.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  3. 03LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 ameliorated LPS-induced apoptosis.

    In plain wordsIn lab cells, SS‑31 reduced the cell death (apoptosis) caused by LPS.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Cell viability and death · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 ameliorated lipopolysaccharide (LPS)-induced loss of cell viability, ROS production, and apoptosis in NP cells.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  4. 04LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, pretreatment with SS‑31 restored mitochondrial dynamics compared with the LPS group.

    In plain wordsIn lab cells, SS‑31 pretreatment restored normal mitochondrial behaviour compared with LPS alone.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial dynamics
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, mitochondrial dynamics and ATP synthesis were restored on pretreatment with SS-31 compared with the LPS group.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  5. 05LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, pretreatment with SS‑31 restored ATP synthesis compared with the LPS group.

    In plain wordsIn lab cells, SS‑31 pretreatment restored cell energy (ATP) production compared with LPS alone.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseATP synthesis
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, mitochondrial dynamics and ATP synthesis were restored on pretreatment with SS-31 compared with the LPS group.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  6. 06LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 stabilized mitochondrial morphology.

    In plain wordsIn lab cells, SS‑31 kept the shape of mitochondria stable.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableMitochondrial morphology
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    For the molecular mechanism research, SS-31 stabilized mitochondrial morphology
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  7. 07LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 inhibited activation of the NF-κB pathway.

    In plain wordsIn lab cells, SS‑31 blocked activation of the NF-κB inflammation pathway.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNF-κB pathway activation
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    inhibited the activation of the NF-κB pathway and the activation of the NLRP3 inflammasome.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  8. 08LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 inhibited activation of the NLRP3 inflammasome.

    In plain wordsIn lab cells, SS‑31 blocked activation of the NLRP3 inflammasome, an inflammation complex.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNLRP3 inflammasome activation
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the activation of the NLRP3 inflammasome.
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.
  9. 09LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 inhibited NLRP3 inflammasome activation by limiting mitochondrial ROS production.

    In plain wordsIn lab cells, SS‑31 blocked the NLRP3 inflammation complex by limiting mitochondrial reactive oxygen species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS dependence of NLRP3 inhibition
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    SS-31 with ROS scavenger NAC
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results indicate that SS-31 could inhibit NLRP3 inflammasome activation by limiting the production of mitochondrial ROS.
    1 context sentence
    Summary · context
    To evaluate whether the inhibition of NLRP3 inflammasome activation by SS-31 is dependent on the clearance of mitochondrial ROS, we comparatively analyzed the activation of NLRP3 inflammasome in NP cells pretreated with SS-31 and the ROS scavenger N-acetyl-L-cysteine (NAC).
  10. 10LabIn vitro (cells)Mechanism

    In nucleus pulposus cells, SS‑31 inhibited LPS-induced pyroptosis and inflammation.

    In plain wordsIn lab cells, SS‑31 reduced a form of inflammatory cell death (pyroptosis) and inflammation caused by LPS.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePyroptosis and inflammation
    Study

    n: not reported in source

    Nucleus pulposus cells with LPS challenge
    Comparator
    LPS group
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 inhibits LPS-induced apoptosis, pyroptosis, and inflammation in NP cells
    1 context sentence
    Summary · context
    Evidence has shown that effects from inflammation and mitochondrial dysfunction lead to pyroptosis and apoptosis of nucleus pulposus (NP) cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.